Factorial Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,600 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the period. Pfizer makes up about 2.5% of Factorial Partners LLC’s holdings, making the stock its 11th biggest position. Factorial Partners LLC’s holdings in Pfizer were worth $2,871,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. V Wealth Advisors LLC lifted its holdings in shares of Pfizer by 6.7% in the third quarter. V Wealth Advisors LLC now owns 36,877 shares of the biopharmaceutical company’s stock valued at $1,613,000 after purchasing an additional 2,308 shares in the last quarter. JGP Global Gestao de Recursos Ltda. lifted its holdings in Pfizer by 91.0% during the third quarter. JGP Global Gestao de Recursos Ltda. now owns 9,288 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 4,426 shares during the period. Game Creek Capital LP lifted its holdings in Pfizer by 9.1% during the third quarter. Game Creek Capital LP now owns 187,750 shares of the biopharmaceutical company’s stock worth $8,216,000 after acquiring an additional 15,650 shares during the period. Commerce Bank lifted its holdings in Pfizer by 3.3% during the third quarter. Commerce Bank now owns 2,474,759 shares of the biopharmaceutical company’s stock worth $108,295,000 after acquiring an additional 80,159 shares during the period. Finally, TRUE Private Wealth Advisors lifted its holdings in Pfizer by 4.7% during the third quarter. TRUE Private Wealth Advisors now owns 129,268 shares of the biopharmaceutical company’s stock worth $5,656,000 after acquiring an additional 5,814 shares during the period. Institutional investors own 67.62% of the company’s stock.
Pfizer Price Performance
NYSE PFE opened at $44.71 on Wednesday. The business’s fifty day moving average is $49.68 and its 200 day moving average is $48.06. Pfizer Inc. has a fifty-two week low of $41.44 and a fifty-two week high of $56.32. The company has a market capitalization of $250.97 billion, a PE ratio of 8.60, a price-to-earnings-growth ratio of 1.11 and a beta of 0.67. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.37 and a current ratio of 1.59.
Pfizer Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Shareholders of record on Friday, January 27th will be issued a dividend of $0.41 per share. The ex-dividend date is Thursday, January 26th. This represents a $1.64 dividend on an annualized basis and a yield of 3.67%. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. Pfizer’s dividend payout ratio is currently 30.77%.
Wall Street Analyst Weigh In
A number of brokerages recently commented on PFE. Credit Suisse Group set a $54.00 price target on Pfizer in a report on Wednesday, January 18th. Wells Fargo & Company downgraded Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $54.00 to $50.00 in a research report on Tuesday, January 17th. StockNews.com began coverage on Pfizer in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. SVB Leerink lifted their price target on Pfizer from $48.00 to $49.00 and gave the company a “market perform” rating in a research report on Thursday, November 3rd. Finally, UBS Group set a $55.00 price objective on Pfizer in a research note on Wednesday, January 18th. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $53.00.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.